BSR_19_0096_S47
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
- ESTROGEN_RESPONSE_EARLY+0.440
- IL2_STAT5_SIGNALING+0.420
- TNFA_SIGNALING_VIA_NFKB+0.410
- ALLOGRAFT_REJECTION+0.390
- ESTROGEN_RESPONSE_LATE+0.380
- COMPLEMENT+0.370
- IL6_JAK_STAT3_SIGNALING+0.360
- ANGIOGENESIS+0.350
- ADIPOGENESIS+0.330
Top 10 suppressed
- MYC_TARGETS_V2-0.300
- PANCREAS_BETA_CELLS-0.210
- MYC_TARGETS_V1-0.200
- SPERMATOGENESIS-0.120
- PROTEIN_SECRETION-0.110
- DNA_REPAIR-0.100
- UNFOLDED_PROTEIN_RESPONSE-0.100
- OXIDATIVE_PHOSPHORYLATION-0.070
- G2M_CHECKPOINT-0.060
- INTERFERON_ALPHA_RESPONSE-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 718de66e-06d2-4c2c-8b2d-e40087c4340c | — | — | 0.848 |
| 2 | BS_593HEWBF | Ganglioglioma | — | 0.848 |
| 3 | EPT0509 | EPN | EPN Tumor | 0.848 |
| 4 | TCGA-60-2707-01A-01R-0851-07 | — | cohortSQ1 | 0.839 |
| 5 | SRR10900576 | — | — | 0.836 |
| 6 | BS_HC5M8JTC | low-grade glioma | — | 0.831 |
| 7 | SRR1331597 | GTEX | — | 0.830 |
| 8 | SRR33346953 | — | — | 0.830 |
| 9 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.829 |
| 10 | BS_S7CZY2CH | low-grade glioma | — | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.440 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.420 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.390 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.380 | Idelalisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.330 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |